How to get a new MRI to your doctor
The Mayo Clinic has approved a new treatment for the chronic pain of multiple sclerosis, a disease that causes debilitating muscle weakness and a progressive loss of vision.
The Mayo Clinic on Wednesday announced the approval of the compound for the treatment of the debilitating condition, which has affected millions of Americans, including a group of people in the Midwest.MOS-6, or monoclonal antibodies, are antibodies that attack the central nervous system.
The compound has been approved by the Food and Drug Administration, which regulates the drug development and manufacturing process.MOMA, the medical device division of the Mayo Clinic, is developing the drug in partnership with biotechnology company Novartis, the company said.
Mammograms, which are used for screening for cancer, are the standard imaging tool in most people with MS, but are not effective in treating symptoms of the disease.MAML is a monocle-shaped antibody that is injected directly into the muscle, where it binds to the protein called MS-2, and blocks its ability to release the neurotransmitter dopamine.
The drug has been shown to slow the onset of the condition in some people, according to the Mayo clinic.
The researchers are working to test whether MAML could be used in people who are not at high risk for MS and to test its effectiveness in treating MS symptoms in people with other diseases.
The new treatment has been developed with help from Mayo Clinic scientists and Mayo Clinic doctors and the Mayo Biomedical Research Institute.
The company is working with Mayo Clinic researchers, including Dr. Robert J. Stoll, the director of the MS Center for Clinical and Translational Research at the Mayo Clinics.MAMA has partnered with Novartic, a global biotechnology corporation, to develop MAM-1 and MAMM-1.
MAMs and MAMS are different monoclates that work together to target MS-1, a protein that is a precursor to MS-6.
The drug blocks this pathway, allowing MS-7, MS-8, and MS-9 to be eliminated, Stoll said.
The MAM compound has the same side effects as MAM drugs, but is effective in some cases, he said.
The side effects are usually mild.
The compound also has a longer shelf life.
The MAM molecules are similar to antibodies that target MS proteins, he added.